| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 33.02 | 0.04 (+0.12%) | 25.69 - 35.44 | 9.6 million (Above Avg) |
Market data as of 4:01PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 33.25 |
|---|---|
| Previous Close | 32.98 |
| Day's Range | 32.90 - 33.29 |
| Market Cap | 55.8B |
| Avg Volume (10 Day) | 8.1M |
| Price/Earnings (Trailing 12 Mo.) | 14.9x |
| Earnings Per Share (Trailing 12 Mo.) | 2.22 |
| Dividend Yield | 0.34 (4.12%) |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Pass |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Pass |
| Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Pass |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Pass |
| Stock is undervalued? | Pass |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
U.S. FDA Approves Bristol-Myers Squibb Devens Biologics Manufacturing Facility for Production of ORENCIA® (abatacept)
Business Wire - Tuesday 05/15/2012 11:00 AM ET
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
Business Wire - Tuesday 05/15/2012 10:00 AM ET
Former Pro Football Coach Bill Cowher Teams Up With Leading Advocacy Groups to Launch Melanoma Exposed™, an Educational Campaign to Raise Awareness of the Most Deadly Form of Skin Cancer
Business Wire - Tuesday 05/15/2012 8:00 AM ET
Former Pro Football Coach Bill Cowher Teams Up with Leading Advocacy Groups to Launch Melanoma Exposed™, an Educational Campaign to Raise Awareness of the Most Deadly Form of Skin Cancer
PR Newswire - Tuesday 05/15/2012 8:00 AM ET
Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership
Business Wire - Monday 05/14/2012 10:00 PM ET
Bristol-Myers Squibb to Present New Data on ORENCIA® (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
Business Wire - Monday 05/14/2012 8:00 AM ET
RBCC Partner n3D Makes Waves With Bio-Assembler
Business Wire - Monday 05/14/2012 5:00 AM ET
RBCC Partner n3D Explores New Business Opportunities at Biomedical Conference
Business Wire - Friday 05/11/2012 5:00 AM ET
| BMY | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 9.12% | |
| Net Income Growth (1yr) | 22.21% | |
| Total Debt/Equity | 0.33 | |
| LT Debt/Equity | 0.32 | |
| Earnings Yield | 6.71% | |
| Price/Sales | 2.59 |
| Company | Last | Change |
|---|---|---|
| Eli Lilly and Co | 40.75 | +0.42% |
| Sanofi SA | 34.29 | -0.90% |
| Abbott Laboratories | 62.55 | +1.07% |
| Impax Laboratories Inc | 21.81 | +0.46% |
| Wuxi Pharmatech (Cayman) Inc | 14.11 | +0.71% |
Data is delayed by at least 15 min.